CTLA4(細胞傷害性Tリンパ球関連タンパク質4)阻害剤の世界市場:単独療法、併用療法

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Monotherapy – Market size and forecast 2018-2023
• Combination therapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Expansion of research indications
• Special drug designations
• Increasing awareness about cancer
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• Bristol-Myers Squibb Co.
• Ono Pharmaceutical Co. Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AstraZeneca Plc – Vendor overview
Exhibit 45: AstraZeneca Plc – Business segments
Exhibit 46: AstraZeneca Plc – Organizational developments
Exhibit 47: AstraZeneca Plc – Geographic focus
Exhibit 48: AstraZeneca Plc – Key offerings
Exhibit 49: AstraZeneca Plc – Key customers
Exhibit 50: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 51: Bristol-Myers Squibb Co. – Business segments
Exhibit 52: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 53: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 54: Bristol-Myers Squibb Co. – Key offerings
Exhibit 55: Bristol-Myers Squibb Co. – Key customers
Exhibit 56: Ono Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 57: Ono Pharmaceutical Co. Ltd. – Business segments
Exhibit 58: Ono Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 59: Ono Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 60: Ono Pharmaceutical Co. Ltd. – Key offerings
Exhibit 61: Ono Pharmaceutical Co. Ltd. – Key customers
Exhibit 62: Validation techniques employed for market sizing
Exhibit 63: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様